Management of Symptomatic Bradycardia

Pharmacologic First‑Line Therapy

• Atropine 0.5–1 mg IV bolus is the initial drug of choice for patients with symptomatic bradycardia and hemodynamic compromise (American College of Cardiology recommendation; Class I) 1

• When coronary ischemia is unlikely, IV catecholamines (isoproterenol, dopamine, dobutamine, or epinephrine) may be used as alternative therapy (Class IIb) 1

• In patients receiving chronic, medically necessary anti‑arrhythmic or β‑blocker therapy who develop symptomatic second‑degree or third‑degree AV block, proceeding directly to permanent pacing without drug washout is reasonable (Class IIa) 1

• Oral theophylline (≈400–600 mg/day) can be considered to increase heart rate and improve symptoms in patients whose sinus node dysfunction is suspected (Class IIb) 1

Second‑Line Interventions When Atropine Fails

• Transcutaneous pacing should be initiated immediately for hemodynamically unstable patients who remain symptomatic after atropine (Class IIb) 2
• Transcutaneous pacing serves as an effective bridge to transvenous pacing or permanent pacemaker implantation (Class IIb) 2
• Analgesic or anxiolytic agents are recommended for conscious patients undergoing transcutaneous pacing (Class IIb) 2
• Effective capture must be confirmed by palpable pulse or arterial waveform monitoring (Class IIb) 2

Temporary Pacing

• Temporary transvenous pacing is reasonable for persistent hemodynamically unstable bradycardia refractory to medical therapy (Class IIa) 2
• Temporary transvenous pacing carries a 14–40 % complication rate; it should be avoided in patients with only mild‑to‑moderate symptoms (Class IIa) 2
• When prolonged temporary pacing is anticipated, an externalized permanent pacing lead is preferred over a traditional temporary transvenous wire because it has a lower complication risk (Class IIa) 2

Permanent Pacing Indications

• Permanent pacing is indicated when symptoms are directly attributable to bradycardia and all reversible causes have been excluded or adequately treated (Class I) 3
• Symptomatic sinus node dysfunction with documented correlation between symptoms and bradycardia warrants permanent pacing (Class I) 3
• Symptomatic bradycardia caused by guideline‑directed medical therapy that cannot be discontinued is an indication for permanent pacing (Class I) 3
• Tachy‑brady syndrome with symptoms attributable to bradycardia is an indication for permanent pacing (Class IIa) [3][1]
• Symptomatic chronotropic incompetence is a reasonable indication for permanent pacing with rate‑responsive programming (Class IIa) [3][1]

Pacing Mode Selection

• In patients with symptomatic sinus node dysfunction, atrial‑based pacing (dual‑chamber or single‑chamber atrial) is recommended over single‑chamber ventricular pacing (Class I, Level B‑R) [3][1]
• For patients with intact AV conduction and no conduction abnormalities, dual‑chamber or single‑chamber atrial pacing is preferred (Class I) [3][1]
• In dual‑chamber pacemaker recipients with intact AV conduction, programming should aim to minimize ventricular pacing (Class IIa) [3][1]

Identification and Treatment of Reversible Causes

• Reversible contributors (e.g., hypothyroidism, electrolyte disturbances, acute myocardial infarction, severe hypothermia, acute infections, elevated intracranial pressure) must be identified and treated before permanent pacing (Class I) 3

• Lyme carditis should be managed with antimicrobial therapy and supportive care, including temporary transvenous pacing if needed, before deciding on permanent pacing (Class I) 1

• Cardiac sarcoidosis presenting with second‑degree or third‑degree AV block warrants permanent pacing without a trial of reversibility (Class IIa) 1

Clinical Pitfalls

• Permanent pacing should not be performed in asymptomatic individuals with sinus bradycardia, sinus pauses due to physiologic vagal tone, or sleep‑related sinus pauses (Class I recommendation to avoid) [3][2]

• Do not delay transcutaneous pacing in unstable patients who fail atropine; rapid escalation is essential (Class I) 2

• Do not implant a permanent pacemaker without first addressing reversible causes, recognizing that many patients with “reversible” complete AV block will ultimately require permanent pacing (Class I) 3

• Weekend admissions are associated with increased use of temporary transvenous pacing, a one‑day delay to permanent pacemaker implantation, and a two‑day longer hospital stay; early weekend permanent pacemaker implantation can mitigate these issues (observational finding) 2

Treatment of Symptomatic Bradycardia

Initial Assessment and Management

• The American Heart Association recommends ensuring adequate oxygenation and treating hypoxemia if present in patients with symptomatic bradycardia 4
• The American College of Cardiology suggests establishing IV access and continuous cardiac monitoring in patients with symptomatic bradycardia 4, 5
• A 12-lead ECG should be obtained to identify the specific rhythm disturbance in patients with symptomatic bradycardia, as recommended by the American Heart Association 4
• It is essential to determine if bradycardia is causing the patient's symptoms, as stated by the American College of Cardiology 4, 5

Pharmacologic Treatment

• The American Heart Association recommends atropine 0.5-1 mg IV bolus as the initial dose for symptomatic bradycardia, with repeat doses every 3-5 minutes as needed, up to a maximum of 3 mg 4, 5, 6
• Atropine is most effective for sinus bradycardia, AV nodal block, or sinus arrest, but may be ineffective for Mobitz type II second-degree or third-degree AV block with wide QRS, as noted by the American College of Cardiology 4, 5
• The American Heart Association advises using atropine cautiously in acute coronary ischemia/MI, as increased heart rate may worsen ischemia or increase infarct size 5

Second-Line Treatments

• The American College of Cardiology recommends initiating transcutaneous pacing immediately in unstable patients unresponsive to atropine 5, 6
• IV catecholamines, such as dopamine or epinephrine, may be used as an alternative or bridge to pacing in patients with symptomatic bradycardia, as suggested by the American Heart Association 5, 6

Definitive Treatment

• The American College of Cardiology indicates that temporary transvenous pacing is reasonable for persistent hemodynamically unstable sinus node dysfunction refractory to medical therapy 7, 8
• Permanent pacemaker placement is recommended for advanced second- or third-degree AV block with symptomatic bradycardia, ventricular dysfunction, or low cardiac output, as stated by the American Heart Association 9
• The American College of Cardiology suggests that symptomatic bradycardia from essential guideline-directed medications that cannot be discontinued is an indication for permanent pacemaker placement 10

Special Situations

• The American Heart Association recommends considering oral theophylline for post-heart transplant bradycardia, as it may restore sinus rate and reduce pacemaker need 7, 8
• Theophylline or aminophylline may be beneficial for spinal cord injury-related bradycardia, which is often refractory to atropine and adrenergic drugs, as noted by the American College of Cardiology 7, 8

Critical Clinical Pitfalls to Avoid

• The American College of Cardiology advises against treating asymptomatic bradycardia, as patients with minimal or infrequent symptoms without hemodynamic compromise should not receive temporary pacing 7, 8
• It is essential to identify and treat reversible causes of bradycardia first, such as medications, hypothyroidism, metabolic abnormalities, and elevated intracranial pressure, as stated by the American Heart Association 10
• The American College of Cardiology recommends avoiding delayed escalation of treatment, such as delaying transcutaneous pacing in unstable patients failing atropine, and considering the underlying rhythm disturbance 5, 6, 4